Testagen TDS Testosterone 5% HypoSpray not checked

Transdermal Delivery Solutions Corp

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
10 active
13 in total · 11 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.”In the company’s words, NCT01894308 on ClinicalTrials.gov
Tested for
Hypogonadotropism (2 trials)
Main trialPhase 2
“This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has been applied and the potential of product to raise serum androgen levels in those women.”In the company’s words, NCT02733133 on ClinicalTrials.gov
Other names
Testosterone

Other drugs for Hypogonadotropism

All 8 drugs for Hypogonadotropism

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials13

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Oct 2027 Product Transference Study of Testagen™ TDS®-Testosterone
Phase 2Not yet recruiting Oct 2027 A Dose Ranging Study to Examine TDS-Testosterone 5%
Phase 1Ended not given Comparative Bioavailability and Bioequivalence of Testosterone Transdermal Gel Versus Testogel® Dosiergel 16.2 mg/g gel: A Single-Dose, Open-Label, Randomized, Full Replicate, Four-Period Crossover Study in Healthy Female Subjects Under Fasting Conditions.
Phase 4Authorised not given Klinefelter syndrome – the effect of Testosterone treatment In PubertY A randomized, double-blind placebo-controlled intervention study ‘The TiPY study’
Phase 4Not authorised not given Transdermal testosterone pretreatment in poor responders with androgen receptor polymorphism undergoing ICSI: A Randomized Clinical Investigation.
Phase 3Authorised not given Transdermal testosterone pretreatment in poor responders with androgen receptor polymorphism undergoing ICSI: A Randomized Clinical Investigation.
Phase 3Ended not given Impact of peri-operative tEstosterone levels oN Functional and oncological Outcomes following RadiCal prostatEctomy (ENFORCE)
Phase 3Authorised not given TRANSADO - Evaluation of the effectiveness of hormonal treatment in adolescents suffering from gender dysphoria
Phase 2Authorised not given Testosterone Replacement Therapy in Women with Turner Syndrome – Endocrine, Cardiovascular, Physiological, Neurocognitive and Genomic effects
Phase 2Authorised not given Prevention of Sexual Offending with Cognitive Behavioral Therapy Alone Versus Therapy Combined with Testosterone Suppression – the PREVENT-MED randomized clinical trial
Phase 2Authorised not given TestICUs : Effects of early testosterone gel administration on physical performance in the critically ill: a randomised double blind clinical trial.
Phase 2Authorised not given Darolutamide with Bipolar Androgen Therapy (BAT) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) – the DaroBAT Trial
Phase 2Authorised not given COMPASS - COpenhagen MenoPAuSe Study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Testagen TDS Testosterone 5% HypoSpray

Following is part of Solo: you see every change to Testagen TDS Testosterone 5% HypoSpray the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in